Article
Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2008
Roué Gaël, López-Guerra Mónica, Milpied Pierre, Pérez-Galán Patricia, Villamor Neus, Montserrat Emili, Campo Elias, Colomer Dolors
Abstract excerpt
PURPOSE: Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are two incurable B-cell lymphoid neoplasms characterized by distinct clinical presentation and evolution. Bendamustine hydrochloride is a multifunctional, alkylating agent with a purine-like ring system that exhibits activity in multiple cancer models, including CLL and MCL, but whose mechanism is only partially described. Our aim was to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
